Perrigo (PRGO) Misses Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
February 26, 2026 6:31 AM ESTDelivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range
Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share1,2 in 2025, Despite Soft Category Consumption
Launching New Operational Enhancement Program - Expected to Deliver Pre-Tax Annualized Savings of $80 million to $100 million
Transitioning to New Reporting Segments Beginning Q1 2026, Aligned to Commercial Operating Model
Issues FY2026 'All In' Outlook; Introduces FY2026 'CORE' Outlook, which Excludes Infant Formula and Previously Announced Divestitures
Fourth Quarter... More



